Interim results of the cediranib trial at NCI

[Olga]

Cediranib for Metastatic Alveolar Soft Part Sarcoma
http://jco.ascopubs.org/content/31/18/2296.full
Conclusion:
In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that cediranib has substantial single-agent activity, producing an ORR of 35% and a disease control rate of 84% at 24 weeks. On the basis of these results, an open-label, multicenter, randomized phase II registration trial is currently being conducted for patients with metastatic ASPS comparing cediranib with another VEGFR inhibitor, sunitinib.
Full text is avail. at the link.